Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109564 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00109564: Completed Phase 2 study, sponsored by Targacept.
NCT00109564 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109564, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.
Interventions
- DRUG ispronicline (nicotinic acetylcholine receptor agonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00109564 record still lists
NCT00109564 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 1 intervention - of which ispronicline (nicotinic acetylcholine receptor agonist) is the first listed.
NCT00109564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00109564 about?
NCT00109564 is a clinical study titled "A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)". The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration a...
What is the current status of trial NCT00109564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2005-01. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00109564?
The interventions under investigation include: ispronicline (nicotinic acetylcholine receptor agonist) (DRUG).
Who is sponsoring clinical trial NCT00109564?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00109564's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia